Johnson & Johnson
Recent News About Johnson & Johnson
-
Johnson & Johnson MedTech launches new tissue-sparing total shoulder replacement system
Johnson & Johnson MedTech has announced the U.S. launch of INHANCE INTACT, a new instrumentation system for total shoulder arthroplasty (TSA) designed to spare the subscapularis tendon during surgery.
-
Johnson & Johnson MedTech launches major ventricular arrhythmia care registry
Johnson & Johnson MedTech has launched the Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias (CORE-VA), a new registry designed to collect data on the treatment of ventricular arrhythmias, including ventricular tachycardia (VT).
-
Johnson & Johnson urges shareholders to reject below-market mini-tender offer from Tutanota
Johnson & Johnson has advised its shareholders to reject an unsolicited mini-tender offer made by Tutanota LLC.
-
Johnson & Johnson to present at UBS Global Healthcare Conference on November 11
Johnson & Johnson announced it will take part in the UBS Global Healthcare Conference on November 11, 2025.
-
Johnson & Johnson presents new data on advanced contact lenses for astigmatism
Johnson & Johnson has announced new research data highlighting the performance of its ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses.
-
FDA approves SIMPONI for pediatric ulcerative colitis treatment
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI (golimumab) for children with moderately to severely active ulcerative colitis (UC), provided they weigh at least 15 kg.
-
Johnson & Johnson announces positive phase 3 results for Tremfya in ulcerative colitis
Johnson & Johnson has released new 48-week results from its Phase 3 ASTRO study, which evaluated the use of TREMFYA (guselkumab) as a subcutaneous induction and maintenance therapy for adults with moderately to severely active ulcerative colitis.
-
Johnson & Johnson reports positive phase 2b results for oral ulcerative colitis drug candidate
Johnson & Johnson has announced new 12-week data from its Phase 2b ANTHEM-UC study of icotrokinra, an investigational oral peptide that targets the IL-23 receptor, in adults with moderately to severely active ulcerative colitis.
-
Johnson & Johnson to join Guggenheim Healthcare Innovation Conference on November 11
Johnson & Johnson announced it will take part in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on November 11, 2025.
-
Johnson & Johnson Foundation increases support for African frontline healthcare workforce
The Johnson & Johnson Foundation has announced an additional $5 million investment in the Africa Frontline First (AFF) Catalytic Fund.
-
Johnson & Johnson announces Phase 3 trial results for seltorexant in depression with insomnia
Johnson & Johnson has released results from a Phase 3 clinical trial evaluating seltorexant, an investigational treatment for adults and elderly patients with major depressive disorder (MDD) who also experience insomnia symptoms.
-
Johnson & Johnson launches new device for treating severe peripheral artery disease in Europe
Johnson & Johnson has announced the European launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy (IVL) Catheter, a new device designed to help treat patients with peripheral artery disease (PAD).
-
FDA approves INLEXZO from Johnson & Johnson for certain types of bladder cancer
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO (gemcitabine intravesical system) for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder...
-
Johnson & Johnson to present at Bernstein healthcare forum on September 24, 2025
Johnson & Johnson has announced its participation in the Bernstein 2nd Annual Healthcare Forum, scheduled for September 24, 2025.
-
Johnson & Johnson appoints former Sherwin-Williams CEO John Morikis to board
Johnson & Johnson has appointed John Morikis, the retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors.
-
Johnson & Johnson highlights unmet needs in maternal fetal immunology at ISUOG Congress
Johnson & Johnson has announced that six abstracts, including an oral poster presentation, will be presented at the 35th International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) World Congress in Cancún, Mexico.
-
Johnson & Johnson schedules Q3 investor call for October 14
Johnson & Johnson announced it will hold an investor conference call on Tuesday, October 14, at 8:30 a.m. Eastern Time to discuss its third-quarter financial results.
-
Johnson & Johnson presents positive results from real-world study on VARIPULSE platform
Johnson & Johnson MedTech has released new data from the VARIPURE substudy of SECURE, a real-world evaluation of its VARIPULSE Platform for pulsed field ablation (PFA) in atrial fibrillation (AF) treatment.
-
Johnson & Johnson reports long-term survival benefit for Impella CP after heart attack
New long-term data from the DanGer Shock randomized controlled trial, presented at the European Society of Cardiology Congress and published in The New England Journal of Medicine, show that routine use of the Impella CP heart pump in patients who...
-
Johnson & Johnson ends phase 2a trial of nipocalimab combo for rheumatoid arthritis
Johnson & Johnson has announced results from its Phase 2a DAISY proof-of-concept study, which evaluated the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in patients with rheumatoid arthritis (RA) who have...